English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

CFDA Approves BioChain's Colorectal Cancer Diagnostic Test

Dec. 8, 2014

Epigenomics AG, the German- American cancer molecular diagnostics company, and BioChain, a leading clinical diagnostics company in cancer and genetic testing in China and the U.S.A., announced on December 08, 2014 that the CFDA approved Epi proColon® for commercialization in China. Epi proColon® is Epigenomics’ non-invasive blood-based diagnostic test for colorectal cancer (CRC) detection based on the Septin9 DNA methylation marker.

The approval was based on a major clinical validation study completed by BioChain in April 2014, which confirmed the previously demonstrated positive clinical performance of Epi proColon®.